(Q43986056)

28 November 2017

title

Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables (English)

1 reference

28 November 2017

1 reference

1 reference

9

1 reference

28 November 2017

Antonio Ciapparelli

6

0 references

Gino Giannaccini

object named as

Gino Giannaccini

3

0 references

Antonio Lucacchini

object named as

Antonio Lucacchini

8

0 references

Liliana Dell'Osso

10

object named as

Liliana Dell'Osso

1 reference

28 November 2017

Lionella Palego

1

1 reference

28 November 2017

Luciano Biondi

2

1 reference

28 November 2017

Nannina Sarno

4

1 reference

28 November 2017

Simona Elmi

5

1 reference

28 November 2017

Giovanni Battista Cassano

7

1 reference

28 November 2017

publication date

1 April 2002

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

28 November 2017

published in

1 reference

28 November 2017

volume

26

1 reference

28 November 2017

issue

3

1 reference

28 November 2017

page(s)

473-480

1 reference

Clozapine--pharmacokinetic investigations and biochemical effects in man.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Clozapine for treatment-refractory mania

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Clozapine as a treatment tool: only in resistant schizophrenic patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Clozapine for Treatment-Refractory Schizophrenia, Schizoaffective Disorder, and Psychotic Bipolar Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Evaluation of treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Influence of patient-related variables on clozapine plasma levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Clozapine: new research on efficacy and mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Simultaneous analysis of clozapine, clomipramine and their metabolites by reversed-phase liquid chromatography.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Cigarette smoking and clinically significant drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

The expanding indications for clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900291-3

7 January 2021

10.1016/S0278-5846(01)00291-3

Identifiers

DOI

1 reference

28 November 2017

1 reference